Búsqueda | BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas

1.

Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer.

Piccart, M J; Gore, M; Ten Bokkel Huinink, W; Van Oosterom, A; Verweij, J; Wanders, J; Franklin, H; Bayssas, M; Kaye, S.

J Natl Cancer Inst ; 87(9): 676-81, 1995 May 03.

Artículo en Inglés | MEDLINE | ID: mdl-7752272

2.

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.

Tomiak, E; Piccart, M J; Kerger, J; Lips, S; Awada, A; de Valeriola, D; Ravoet, C; Lossignol, D; Sculier, J P; Auzannet, V.

J Clin Oncol ; 12(7): 1458-67, 1994 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-7912725

3.

Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.

Piccart, M J; Klijn, J; Paridaens, R; Nooij, M; Mauriac, L; Coleman, R; Bontenbal, M; Awada, A; Selleslags, J; Van Vreckem, A; Van Glabbeke, M.

J Clin Oncol ; 15(9): 3149-55, 1997 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-9294478

4.

Use and abuse of taxanes in the management of metastatic breast cancer.

Bernard-Marty, C; Cardoso, F; Piccart, M J.

Eur J Cancer ; 39(14): 1978-89, 2003 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-12957452

5.

Taxanes in the adjuvant treatment of breast cancer: why not yet?

Piccart, M J; Lohrisch, C; Duchateau, L; Buyse, M.

J Natl Cancer Inst Monogr ; (30): 88-95, 2001.

Artículo en Inglés | MEDLINE | ID: mdl-11773299

6.

Future perspectives of docetaxel (Taxotere) in front-line therapy.

Piccart, M J; Di Leo, A.

Semin Oncol ; 24(4 Suppl 10): S10-27-S10-33, 1997 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-9275004

7.

["Taxanes: an action mechanism at the cellular level, significant clinical progress in the treatment of cancers of the ovary and breast"]. / "Les taxanes: d'un mécanisme d'action original à l'échelon cellulaire, à des progrès cliniques significatifs dans le traitement des cancers de l'ovaire et du sein".

Piccart, M J.

Bull Mem Acad R Med Belg ; 153(5-6): 285-92; discussion 292-4, 1998.

Artículo en Francés | MEDLINE | ID: mdl-9988934

8.

[Optimal therapeutic strategies in ovarian epithelial cancer in 1997]. / Stratégies thérapeutiques optimales dans le cancer épithélial de l'ovaire en 1997.

Piccart, M J; Nogaret, J M.

Rev Med Brux ; 18(4): 198-203, 1997 Sep.

Artículo en Francés | MEDLINE | ID: mdl-9411642

9.

Taxoid compounds in breast cancer: current status and future prospects.

Piccart, M J.

Cancer Treat Res ; 78: 185-207, 1995.

Artículo en Inglés | MEDLINE | ID: mdl-8595143

10.

Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG).

Biganzoli, L; Goldhirsch, A; Straehle, C; Castiglione-Gertsch, M; Therasse, P; Aapro, M; Minisini, A; Piccart, M J.

Ann Oncol ; 15(2): 207-10, 2004 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-14760110

11.

HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.

Di Leo, A; Chan, S; Paesmans, M; Friedrichs, K; Pinter, T; Cocquyt, V; Murray, E; Bodrogi, I; Walpole, E; Lesperance, B; Korec, S; Crown, J; Simmonds, P; Von Minckwitz, G; Leroy, J Y; Durbecq, V; Isola, J; Aapro, M; Piccart, M J; Larsimont, D.

Breast Cancer Res Treat ; 86(3): 197-206, 2004 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-15567936

12.

Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients.

Bernard-Marty, C; Mano, M; Paesmans, M; Accettura, C; Munoz-Bermeo, R; Richard, T; Kleiber, K; Cardoso, F; Lobelle, J P; Larsimont, D; Piccart, M J; Di Leo, A.

Ann Oncol ; 14(5): 693-8, 2003 May.

Artículo en Inglés | MEDLINE | ID: mdl-12702521

13.

Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC).

Kusenda, Z; Kerger, J; Awada, A; Geurs, F; Van Vreckem, A; Habboubi, N; Piccart, M J.

Support Care Cancer ; 5(5): 414-6, 1997 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-9322355

14.

A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.

Di Leo, A; Crown, J; Nogaret, J M; Duffy, K; Bartholomeus, S; Dolci, S; Rowan, S; O'Higgins, N; Paesmans, M; Larsimont, D; Riva, A; Piccart, M J.

Ann Oncol ; 11(2): 169-75, 2000 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-10761751

15.

HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.

Di Leo, A; Larsimont, D; Gancberg, D; Jarvinen, T; Beauduin, M; Vindevoghel, A; Michel, J; Focan, C H; Ries, F; Gobert, P H; Closon-Dejardin, M T; Dolci, S; Rouas, G; Paesmans, M; Lobelle, J P; Isola, J; Piccart, M J.

Ann Oncol ; 12(8): 1081-9, 2001 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-11583189

BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas - MTCI

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar: